JP2022529700A5 - - Google Patents
Info
- Publication number
- JP2022529700A5 JP2022529700A5 JP2021562085A JP2021562085A JP2022529700A5 JP 2022529700 A5 JP2022529700 A5 JP 2022529700A5 JP 2021562085 A JP2021562085 A JP 2021562085A JP 2021562085 A JP2021562085 A JP 2021562085A JP 2022529700 A5 JP2022529700 A5 JP 2022529700A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- formula
- pharmaceutically acceptable
- cocrystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837331P | 2019-04-23 | 2019-04-23 | |
| US62/837,331 | 2019-04-23 | ||
| PCT/US2020/029483 WO2020219650A1 (en) | 2019-04-23 | 2020-04-23 | Degraders of cyclin-dependent kinase 12 (cdk12) and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022529700A JP2022529700A (ja) | 2022-06-23 |
| JP2022529700A5 true JP2022529700A5 (enExample) | 2023-05-01 |
Family
ID=72941778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021562085A Pending JP2022529700A (ja) | 2019-04-23 | 2020-04-23 | サイクリン依存性キナーゼ１２（ｃｄｋ１２）の分解剤およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12662464B2 (enExample) |
| EP (1) | EP3958861A4 (enExample) |
| JP (1) | JP2022529700A (enExample) |
| CN (1) | CN113993519B (enExample) |
| AU (1) | AU2020263390B2 (enExample) |
| CA (1) | CA3132387A1 (enExample) |
| WO (1) | WO2020219650A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| US11458149B1 (en) | 2019-05-31 | 2022-10-04 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
| BR112021024108A2 (pt) | 2019-05-31 | 2022-03-22 | Ikena Oncology Inc | Inibidores de tead e usos dos mesmos |
| EP3976621A4 (en) * | 2019-06-03 | 2023-11-15 | Regents of the University of Minnesota | COMPOUNDS THAT DEGRADE KINASES AND THEIR USES |
| CN114727974A (zh) | 2019-07-30 | 2022-07-08 | 艾科尼佐治疗股份有限公司 | Hdac6抑制剂及其用途 |
| WO2022120355A1 (en) * | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead degraders and uses thereof |
| WO2022169985A1 (en) | 2021-02-03 | 2022-08-11 | Eikonizo Therapeutics, Inc. | Hdac6 inhibitors and uses thereof |
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| AU2022362494A1 (en) * | 2021-10-14 | 2024-05-23 | Cullgen (Shanghai), Inc. | Modified proteins and protein degraders |
| TW202329937A (zh) | 2021-12-03 | 2023-08-01 | 美商英塞特公司 | 雙環胺ｃｋ１２抑制劑 |
| US12084453B2 (en) | 2021-12-10 | 2024-09-10 | Incyte Corporation | Bicyclic amines as CDK12 inhibitors |
| WO2023143482A1 (zh) * | 2022-01-29 | 2023-08-03 | 上海辉启生物医药科技有限公司 | 2-氨基嘧啶类化合物或其盐及其制备方法和用途 |
| AU2023250964A1 (en) | 2022-04-08 | 2024-11-07 | Eikonizo Therapeutics, Inc. | Oxadiazole hdac6 inhibitors and uses thereof |
| CA3251059A1 (en) | 2022-05-02 | 2023-11-09 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions, systems and methods for modulating a target gene |
| CN121358732A (zh) * | 2023-03-07 | 2026-01-16 | 睿跃生物科技有限公司 | 治疗癌症的化合物和方法 |
| CN116768860A (zh) * | 2023-06-05 | 2023-09-19 | 西安交通大学医学院第一附属医院 | 一类靶向降解cd26的化合物、其制备方法与应用 |
| CN119950745B (zh) * | 2025-01-14 | 2025-10-17 | 浙江大学 | 一种药物组合物及其在制备抗肿瘤药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102438072B1 (ko) * | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| WO2015058126A1 (en) * | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| WO2015058163A2 (en) * | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| MX358346B (es) * | 2014-04-04 | 2018-08-15 | Syros Pharmaceuticals Inc | Inhibidores de la quinasa dependiente de ciclina 7 (cdk7). |
| US9694084B2 (en) * | 2014-12-23 | 2017-07-04 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| BR112018008918A8 (pt) | 2015-11-02 | 2019-02-26 | Univ Yale | compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos |
| AU2017254702B2 (en) * | 2016-04-22 | 2020-12-24 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 9 (CDK9) by conjugation of CDK9 inhibitors with E3 ligase ligand and methods of use |
| WO2017185031A1 (en) * | 2016-04-22 | 2017-10-26 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use |
| SG11201900328WA (en) * | 2016-07-13 | 2019-02-27 | Jason Marineau | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| JP7258748B2 (ja) | 2016-11-22 | 2023-04-17 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼ１２（ｃｄｋ１２）の阻害剤およびその使用 |
| AU2019309909A1 (en) | 2018-07-23 | 2021-02-04 | Dana-Farber Cancer Institute, Inc. | Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of use |
-
2020
- 2020-04-23 JP JP2021562085A patent/JP2022529700A/ja active Pending
- 2020-04-23 WO PCT/US2020/029483 patent/WO2020219650A1/en not_active Ceased
- 2020-04-23 CN CN202080044331.9A patent/CN113993519B/zh active Active
- 2020-04-23 US US17/604,852 patent/US12662464B2/en active Active
- 2020-04-23 CA CA3132387A patent/CA3132387A1/en active Pending
- 2020-04-23 EP EP20795755.6A patent/EP3958861A4/en active Pending
- 2020-04-23 AU AU2020263390A patent/AU2020263390B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102505664B1 (ko) | Ezh2 저해제 및 e3 리가제 바인더를 포함하는 화합물 및 이를 유효성분으로 함유하는 ezh2 관련 질환의 예방 또는 치료용 약학적 조성물 | |
| ES2561598T3 (es) | Derivados de indazol sustituidos con benzodioxinilo | |
| JP2020533288A5 (enExample) | ||
| JP2022507020A5 (enExample) | ||
| JP2022541467A (ja) | オーロラキナーゼ阻害剤およびその使用 | |
| CA2810706C (en) | Substituted amide compound | |
| ES2552684T3 (es) | Nuevos compuestos de imidazolidina como moduladores del receptor de andrógenos | |
| JP2021523225A5 (enExample) | ||
| EP4050008A1 (en) | Pyridazinone or pyridazine compound and derivative and pharmaceutical composition thereof | |
| JP2015531773A (ja) | スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用 | |
| JP2022548250A5 (enExample) | ||
| EP3119781B1 (en) | Compounds which inhibit rna polymerase, compositions including such compounds, and their use | |
| JP2020517595A (ja) | サイクリン依存性キナーゼｃｄｋ９の新規阻害剤 | |
| ES3062809T3 (en) | Process for preparing aficamten | |
| WO2019012172A1 (es) | Nuevos derivados heteroaryl amida como inhibidores selectivos de histona deacetilasa 1 y 2 (hdac1/2) | |
| FR2943669A1 (fr) | Derives de nicotinamide,leur preparation et leur application en therapeutique | |
| JP2017504595A5 (enExample) | ||
| JP2018534355A (ja) | Ｐｐａｒアゴニスト、化合物、医薬組成物、及びその使用方法 | |
| JP2021529174A5 (enExample) | ||
| JP2021534254A5 (ja) | 心臓弁疾患を治療するための医薬組成物 | |
| JP2024517183A5 (enExample) | ||
| CZ2003239A3 (cs) | Způsob přípravy azacykloalkanoylaminothiazolů | |
| JP2021534084A5 (enExample) | ||
| ES2991258T3 (es) | Procedimientos y productos intermedios para producir compuestos de diazaespiro-lactama | |
| EP3743419B1 (en) | Novel compounds for the treatment of parasitic infections |